Intravenous ascorbic acid as an adjuvant to interleukin-2 immunotherapy

Interleukin-2 (IL-2) therapy has been demonstrated to induce responses in 10-20% of advanced melanoma and renal cell carcinoma patients, which translates into durable remissions in up to half of the responsers. Unfortunately the use of IL-2 has been associated with severe toxicity and death. It has...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Wagner, Samuel C, Markosian, Boris, Ajili, Naseem, Dolan, Brandon R, Kim, Andy J, Alexandrescu, Doru T, Dasanu, Constantin A, Minev, Boris, Koropatnick, James, Marincola, Francesco M, Riordan, Neil H
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2014
Assuntos:
Review
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4028098/
https://ncbi.nlm.nih.gov/pubmed/24884532
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-12-127
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados